The Indian pharma industry is abuzz with news of the rapidly growing drug discovery services market, expected to reach a value of $6.7 billion by 2030. This growth spurt is driven by increasing investments in research and development (R&D) and the government’s push for innovation in healthcare.
The market is expected to witness a CAGR of 10.5% from 2025 to 2030, making it one of the fastest-growing markets in the world. This growth is attributed to the increasing demand for innovative drugs and therapies to address various diseases, including cancer, diabetes, and cardiovascular diseases.
Key Drivers of Growth
The Indian government’s initiatives to promote R&D in the pharma sector, such as the Biotechnology Policy 2005 and the National Pharmaceutical Pricing Policy 2011, have contributed to the growth of the drug discovery services market.
Additionally, the increasing partnership between Indian pharma companies and global players is also driving the growth of the market.
Furthermore, the Indian government’s push for innovation in healthcare, including the launch of the National Health Stack and the Ayushman Bharat Scheme, is expected to create new opportunities for the drug discovery services market.
Market Segmentation
The drug discovery services market can be segmented into different processes, including target identification, lead optimization, and pre-clinical development.
The market can also be segmented into different types, including discovery services, development services, and manufacturing services.
The market can also be segmented by geography, with India, China, and the US being the key markets.
The growth of the drug discovery services market is expected to have a positive impact on the Indian economy, creating new job opportunities and driving economic growth.
The market is expected to witness significant growth in the coming years, driven by increasing investments in R&D and the government’s push for innovation in healthcare.
As the market continues to grow, it is expected to create new opportunities for pharma companies, research institutions, and investors.